Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Other Accumulated Expenses (2016 - 2025)

Cytokinetics (CYTK) has disclosed Other Accumulated Expenses for 14 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 64.04% to $2.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.0 million, a 64.04% decrease, with the full-year FY2023 number at $10.6 million, up 69.65% from a year prior.
  • Other Accumulated Expenses was $2.0 million for Q3 2025 at Cytokinetics, down from $8.8 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $10.6 million in Q4 2023 to a low of $1.5 million in Q4 2021.
  • A 5-year average of $6.4 million and a median of $6.3 million in 2023 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 304.16% in 2022, then tumbled 64.04% in 2025.
  • Cytokinetics' Other Accumulated Expenses stood at $1.5 million in 2021, then surged by 304.16% to $6.2 million in 2022, then soared by 69.65% to $10.6 million in 2023, then crashed by 47.64% to $5.5 million in 2024, then crashed by 64.04% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Other Accumulated Expenses are $2.0 million (Q3 2025), $8.8 million (Q2 2025), and $8.5 million (Q1 2025).